This biopharmaceutical company in Salt Lake City focuses on the clinical development of targeted therapies for cancer, specifically addressing the lack of effective treatment options for patients with unmet medical needs. By utilizing precision medicine approaches, the company aims to enhance treatment efficacy and improve patient outcomes in oncology.
Funding
$520K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients lack effective treatment options, particularly those with tumors expressing specific biomarkers or those resistant to existing therapies. The traditional drug development process is lengthy and has a low success rate, leaving a significant gap between promising preclinical candidates and approved therapeutics.
Solution
Algok Bio is a biopharmaceutical company focused on in-licensing and developing promising preclinical oncology assets into clinical-stage and commercialized therapies. They identify and acquire candidates with strong potential for success, focusing on precision medicine approaches and biomarker-driven strategies. Algok Bio's lead programs include Idetrexed, a small-molecule FRα-targeted inhibitor, and AGK-102, an anti-TM4SF4 monoclonal antibody targeting cancer stem cells. By de-risking asset acquisition and leveraging their drug development expertise, Algok Bio aims to bridge the gap between drug discovery and delivering improved treatment options to patients.
Target Audience
The primary target audience includes pharmaceutical companies seeking to license late-stage clinical assets, as well as patients with cancers expressing FRα or TM4SF4 who are in need of more effective treatment options.
Features
- Idetrexed: A small-molecule inhibitor that selectively accumulates in cancer cells overexpressing Folate Receptor alpha (FRα), inhibiting Thymidylate Synthase (TS) and blocking cancer cell proliferation.
- AGK-102: A first-in-class anti-TM4SF4 monoclonal antibody targeting cancer stem cells, suppressing tumor growth by down-regulating OPN and blocking IGF1R signaling.
- Focus on precision medicine approaches, targeting specific biomarkers to enhance treatment efficacy and minimize off-target toxicity.
- Clinical development programs for Idetrexed include monotherapy and combination therapy (with Olaparib) strategies.
- AGK-102 is in preclinical development with plans for CMC development and IND-enabling studies.
- Strategic in-licensing and acquisition of preclinical assets to build a pipeline of promising oncology therapeutics.